Mechanisms overseeing myeloid-derived suppressor cell production in neoplastic disease

Cancer Immunology, Immunotherapy

Volumn 66, Issue 8, 2017, Pages 989-996

  Netherby, Colleen S ^a   Abrams, Scott I ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Cancer; IRF8; MDSCs; Myelopoiesis; Regulatory myeloid cells

Indexed keywords

INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; STAT3 PROTEIN; INTERFERON REGULATORY FACTOR;

CANCER IMMUNOTHERAPY; CELL MATURATION; DOWN REGULATION; FUTUROLOGY; HUMAN; IMMUNOREGULATION; META ANALYSIS (TOPIC); MOUSE MODEL; MYELOID-DERIVED SUPPRESSOR CELL; NEOPLASM; NONHUMAN; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW (TOPIC); TREATMENT RESPONSE; TUMOR IMMUNITY; ANIMAL; CARCINOGENESIS; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOUSE; NEOPLASMS; NEUTROPHIL; PHYSIOLOGY; PROCEDURES; TUMOR ESCAPE;

ANIMALS; CARCINOGENESIS; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY; INTERFERON REGULATORY FACTORS; MICE; MYELOID-DERIVED SUPPRESSOR CELLS; NEOPLASMS; NEUTROPHILS; TUMOR ESCAPE;

EID: 85013414265     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-017-1963-5     Document Type: Review

References (51)

1. Bronte V, Brandau S, Chen SH et al (2016) Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun 7:12150
2. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V (2012) Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12:253–268
3. Condamine T, Mastio J, Gabrilovich DI (2015) Transcriptional regulation of myeloid-derived suppressor cells. J Leukoc Biol 98:913–922
4. Messmer MN, Netherby CS, Banik D, Abrams SI (2015) Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy. Cancer Immunol Immunother 64:1–13
5. Marvel D, Gabrilovich DI (2015) Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest 125:3356–3364
6. Gentles AJ, Newman AM, Liu CL et al (2015) The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 21:938–945
7. Sagiv JY, Michaeli J, Assi S et al (2015) Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer. Cell Rep 10:562–573
8. Wu WC, Sun HW, Chen HT et al (2014) Circulating hematopoietic stem and progenitor cells are myeloid-biased in cancer patients. Proc Natl Acad Sci USA 111:4221–4226
9. Rodriguez PC, Ernstoff MS, Hernandez C et al (2009) Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 69:1553–1560
10. Waight JD, Netherby C, Hensen ML et al (2013) Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. J Clin Invest 123:4464–4478
11. Templeton AJ, McNamara MG, Seruga B et al (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 106:dju124
12. Sonda N, Chioda M, Zilio S, Simonato F, Bronte V (2011) Transcription factors in myeloid-derived suppressor cell recruitment and function. Curr Opin Immunol 23:279–285
13. Waight JD, Hu Q, Miller A, Liu S, Abrams SI (2011) Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. PLoS One 6:e27690
14. Solito S, Falisi E, Diaz-Montero CM et al (2011) A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood 118:2254–2265
15. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI (2008) Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 181:5791–5802
16. Almand B, Resser JR, Lindman B et al (2000) Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 6:1755–1766
17. Capietto AH, Kim S, Sanford DE et al (2013) Down-regulation of PLCgamma2-beta-catenin pathway promotes activation and expansion of myeloid-derived suppressor cells in cancer. J Exp Med 210:2257–2271
18. Farren MR, Carlson LM, Netherby CS et al (2014) Tumor-induced STAT3 signaling in myeloid cells impairs dendritic cell generation by decreasing PKCbetaII abundance. Sci Signal 7:ra16
19. Papaspyridonos M, Matei I, Huang Y et al (2015) Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation. Nat Commun 6:6840
20. Abrams SI, Waight JD (2012) Identification of a G-CSF-Granulocytic MDSC axis that promotes tumor progression. Oncoimmunology 1:550–551
21. Paschall AV, Zhang R, Qi CF et al (2015) IFN regulatory factor 8 represses GM-CSF expression in T cells to affect myeloid cell lineage differentiation. J Immunol 194:2369–2379
22. Stewart TJ, Abrams SI (2007) Altered immune function during long-term host-tumor interactions can be modulated to retard autochthonous neoplastic growth. J Immunol 179:2851–2859
23. Stewart TJ, Greeneltch KM, Reid JE et al (2009) Interferon regulatory factor-8 modulates the development of tumour-induced CD11b+ Gr-1+ myeloid cells. J Cell Mol Med 13:3939–3950
24. Stewart TJ, Liewehr DJ, Steinberg SM, Greeneltch KM, Abrams SI (2009) Modulating the expression of IFN regulatory factor 8 alters the protumorigenic behavior of CD11b+ Gr-1+ myeloid cells. J Immunol 183:117–128
25. Waight JD, Banik D, Griffiths EA, Nemeth MJ, Abrams SI (2014) Regulation of the interferon regulatory factor-8 (IRF-8) tumor suppressor gene by the signal transducer and activator of transcription 5 (STAT5) transcription factor in chronic myeloid leukemia. J Biol Chem 289:15642–15652
26. Holtschke T, Lohler J, Kanno Y et al (1996) Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 87:307–317
27. Tamura T, Nagamura-Inoue T, Shmeltzer Z, Kuwata T, Ozato K (2000) ICSBP directs bipotential myeloid progenitor cells to differentiate into mature macrophages. Immunity 13:155–165
28. Schiavoni G, Mattei F, Sestili P et al (2002) ICSBP is essential for the development of mouse type I interferon-producing cells and for the generation and activation of CD8alpha(+) dendritic cells. J Exp Med 196:1415–1425
29. Tsujimura H, Nagamura-Inoue T, Tamura T, Ozato K (2002) IFN consensus sequence binding protein/IFN regulatory factor-8 guides bone marrow progenitor cells toward the macrophage lineage. J Immunol 169:1261–1269
30. Aliberti J, Schulz O, Pennington DJ et al (2003) Essential role for ICSBP in the in vivo development of murine CD8alpha+ dendritic cells. Blood 101:305–310
31. Tsujimura H, Tamura T, Gongora C et al (2003) ICSBP/IRF-8 retrovirus transduction rescues dendritic cell development in vitro. Blood 101:961–969
32. Tsujimura H, Tamura T, Ozato K (2003) Cutting edge: IFN consensus sequence binding protein/IFN regulatory factor 8 drives the development of type I IFN-producing plasmacytoid dendritic cells. J Immunol 170:1131–1135
33. Watowich SS, Liu YJ (2010) Mechanisms regulating dendritic cell specification and development. Immunol Rev 238:76–92
34. Becker AM, Michael DG, Satpathy AT, Sciammas R, Singh H, Bhattacharya D (2012) IRF-8 extinguishes neutrophil production and promotes dendritic cell lineage commitment in both myeloid and lymphoid mouse progenitors. Blood 119:2003–2012
35. Tamura T, Kurotaki D, Koizumi S (2015) Regulation of myelopoiesis by the transcription factor IRF8. Int J Hematol 101:342–351
36. Hambleton S, Salem S, Bustamante J et al (2011) IRF8 mutations and human dendritic-cell immunodeficiency. N Engl J Med 365:127–138
37. Salem S, Langlais D, Lefebvre F et al (2014) Functional characterization of the human dendritic cell immunodeficiency associated with the IRF8(K108E) mutation. Blood 124:1894–1904
38. Kurotaki D, Osato N, Nishiyama A et al (2013) Essential role of the IRF8-KLF4 transcription factor cascade in murine monocyte differentiation. Blood 121:1839–1849
39. Kurotaki D, Yamamoto M, Nishiyama A et al (2014) IRF8 inhibits C/EBPalpha activity to restrain mononuclear phagocyte progenitors from differentiating into neutrophils. Nat Commun 5:4978
40. Wang H, Yan M, Sun J et al (2014) A reporter mouse reveals lineage-specific and heterogeneous expression of IRF8 during lymphoid and myeloid cell differentiation. J Immunol 193:1766–1777
41. Zhang H, Nguyen-Jackson H, Panopoulos AD, Li HS, Murray PJ, Watowich SS (2010) STAT3 controls myeloid progenitor growth during emergency granulopoiesis. Blood 116:2462–2471
42. Manz MG, Boettcher S (2014) Emergency granulopoiesis. Nat Rev Immunol 14:302–314
43. Panopoulos AD, Watowich SS (2008) Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and ‘emergency’ hematopoiesis. Cytokine 42:277–288
44. Hirai H, Zhang P, Dayaram T et al (2006) C/EBPbeta is required for ‘emergency’ granulopoiesis. Nat Immunol 7:732–739
45. Marigo I, Bosio E, Solito S et al (2010) Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 32:790–802
46. Strauss L, Sangaletti S, Consonni FM et al (2015) RORC1 regulates tumor-promoting “emergency” granulo-monocytopoiesis. Cancer Cell 28:253–269
47. Wu L, Yan C, Czader M et al (2012) Inhibition of PPARgamma in myeloid-lineage cells induces systemic inflammation, immunosuppression, and tumorigenesis. Blood 119:115–126
48. de Haas N, de Koning C, Spilgies L, de Vries IJ, Hato SV (2016) Improving cancer immunotherapy by targeting the STATe of MDSCs. Oncoimmunology 5:e1196312
49. Kusmartsev S, Su Z, Heiser A et al (2008) Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res 14:8270–8278
50. Lee JM, Seo JH, Kim YJ, Kim YS, Ko HJ, Kang CY (2012) The restoration of myeloid-derived suppressor cells as functional antigen-presenting cells by NKT cell help and all-trans-retinoic acid treatment. Int J Cancer 131:741–751
51. Iclozan C, Antonia S, Chiappori A, Chen DT, Gabrilovich D (2013) Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother 62:909–918